Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir K Gupta

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
BMC Infectious Diseases|August 22, 2025
Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trialsCissy M Kityo, Samir K Gupta, Princy N Kumar, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 28, 2022
Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic ReviewBrittanny M Polanka, Samir K Gupta, Kaku A So-Armah, et al.
Gastroenterology|April 6, 2007
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin, Regine Rouzier, Frank Wagner, et al.
AIDS (London, England)|March 22, 2018
Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected menFrank J Palella, Xiuhong Li, Samir K Gupta, et al.
Journal of Clinical Pharmacology|October 5, 2002
Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunctionSamir K Gupta, Amy L Pittenger, Suzanne K Swan, et al.
AIDS Research and Human Retroviruses|February 23, 2012
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg, Pablo Tebas, Edgar Turner Overton, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224sSamir K Gupta, Eunice Yeh, Douglas W Kitch, et al.
Clinical Pharmacology and Therapeutics|November 2, 2019
Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure ProphylaxisStephanie N Liu, Brandon T Gufford, Jessica Bo Li Lu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 27, 2007
Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western KenyaKara Wools-Kaloustian, Samir K Gupta, Eva Muloma, et al.
Journal of Leukocyte Biology|May 28, 2017
BCL6 represses antiviral resistance in follicular T helper cellsTohti Amet, Young Min Son, Li Jiang, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
BMC Infectious Diseases|August 22, 2025
Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trialsCissy M Kityo, Samir K Gupta, Princy N Kumar, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 28, 2022
Examining Depression as a Risk Factor for Cardiovascular Disease in People with HIV: A Systematic ReviewBrittanny M Polanka, Samir K Gupta, Kaku A So-Armah, et al.
Gastroenterology|April 6, 2007
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin, Regine Rouzier, Frank Wagner, et al.
AIDS (London, England)|March 22, 2018
Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected menFrank J Palella, Xiuhong Li, Samir K Gupta, et al.
Journal of Clinical Pharmacology|October 5, 2002
Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunctionSamir K Gupta, Amy L Pittenger, Suzanne K Swan, et al.
AIDS Research and Human Retroviruses|February 23, 2012
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg, Pablo Tebas, Edgar Turner Overton, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224sSamir K Gupta, Eunice Yeh, Douglas W Kitch, et al.
Clinical Pharmacology and Therapeutics|November 2, 2019
Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure ProphylaxisStephanie N Liu, Brandon T Gufford, Jessica Bo Li Lu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 27, 2007
Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western KenyaKara Wools-Kaloustian, Samir K Gupta, Eva Muloma, et al.
Journal of Leukocyte Biology|May 28, 2017
BCL6 represses antiviral resistance in follicular T helper cellsTohti Amet, Young Min Son, Li Jiang, et al.
Pageof 12